• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Master- og hovedoppgaver / Master thesis
  • Master i næringsrettet bioteknologi / Master of applied and commercial biotechnology M2NRBIOTEK
  • View Item
  •   Home
  • Master- og hovedoppgaver / Master thesis
  • Master i næringsrettet bioteknologi / Master of applied and commercial biotechnology M2NRBIOTEK
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Diagnostics of inflammatory bowel disease using fecal microbiota: Diagnostic markers and commercial potential

Frøyland, Caroline Jevanord
Master thesis
Thumbnail
View/Open
Frøyland.PDF (1.625Mb)
URI
http://hdl.handle.net/11250/132341
Date
2010
Metadata
Show full item record
Collections
  • Master i næringsrettet bioteknologi / Master of applied and commercial biotechnology M2NRBIOTEK [40]
Abstract
Establishing the diagnosis of Inflammatory Bowel Disease (IBD) with its two main sub forms

Crohn‟s Disease (CD) and Ulcerative colitis (UC) are based on medical history, clinical

evaluation, laboratory tests, endoscopy, radiology and histology. However no gold standard

exists. The lack of appropriate diagnostic tools leads to delayed and incorrect treatment of

IBD patients. A substantial amount of patients diagnosed as CD are later reclassified as UC

and opposite. Also the type of colitis remains unclassified in many patients. In addition, non-

IBD patients presenting with similar symptoms as IBD are unnecessarily investigated with

invasive tests leading to increased hospitals costs.

The cause of IBD is not yet completely described, but most evidence points to a combination

of genetic predisposition, immunological factors, environmental triggers, and gastro intestinal

(GI) microbes. However, neither the types of microbes responsible for the diseases nor

changes in the microbiota as a result of the diseases have been sufficiently identified. The aim

of this thesis was to evaluate the potential of using the fecal microbiota for IBD diagnostics.

This was achieved through a combination of a literature study, lab study and investigations of

the commercial potential including a patent search.

The literature study revealed conflicting evidence related to the amounts of bacteria in IBD

patients relative to controls. Nevertheless, a majority of the articles agreed in decreased

amounts of Clostridia species and increased amounts of Gammaproteobacteria species in the

GI microbiota of IBD patients.

The lab study comprised an evaluation of a genetic test, GA-map™, commercialized by

Genetic Analysis AS (GA). By using variable regions in the 16S rRNA gene, simultaneous

detection and identification of multiple bacteria in a complex mixture of DNA is possible.

Probes and analytic methods are suitable for several types of diagnostic tests among other

IBD. A sequence analysis of fecal samples from 152 IBD patients and 105 non-IBD controls

was performed. Significantly a probe detecting increased relative amounts of Proteobacteria

and Bacteroidetes species was identified as a new possible diagnostic test for CD patients.

A search in European and American patent databases revealed several patents related to IBD

diagnostics. Especially important, a patent application from George Mason University comprised claims referring to IBD diagnostics by using the microbial community of the

digestive tract and lumen. If issued, this application could influence the freedom to operate to

companies focusing on bacterial markers in IBD diagnostics. Few other patents or patent

applications from the search query include claims for identification of bacteria in fecal

samples.

A concluding remark from examining the commercial potential of IBD diagnostics in this

thesis is to tailor make a diagnostic test separating IBD from irritating bowel syndrome (IBS),

a common functional disease frequently confused with IBD. Based on estimations of price

and profit per test, a €7Mill research budget was recommended for the normal case scenario.

Finally it is concluded that development of a diagnostic test based on fecal microbiota has a

commercial potential within the proposed framework.
Description
Mastergradsoppgave i næringsrettet bioteknologi, Avdeling for lærerutdanning og naturvitenskap, Høgskolen i Hedmark, 2010. Master of applied and commercial biotechnology.

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit